Welcome to our dedicated page for Cellular news (Ticker: CBMG), a resource for investors and traders seeking the latest updates and insights on Cellular stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellular's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellular's position in the market.
Cellular Biomedicine Group (NASDAQ: CBMG) presented its poster titled "Selecting Clinical Lead of TCRs Targeting Alpha-Fetoprotein-Positive Liver Cancer on Balance of Risk and Benefit" at the 2020 AACR annual meeting held virtually from June 22-24. The poster discusses C-TCR055, CBMG's proprietary T cell receptor targeting alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC). Preclinical studies indicate C-TCR055 possesses a strong safety profile and anti-tumor activity. A Phase I clinical trial is currently ongoing at Fudan University for patients with unresectable HCC (NCT03971747).
